Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 16, 2021

View Archived Issues

Zeolitic imidazolate frameworks for sustained checkpoint inhibitor release in cancer immunotherapy

Preclinical results of an ACE2-interacting domain of SARS-CoV-2 peptide for COVID-19 treatment

Mucolipidosis type II AAV9 gene therapy demonstrates safety in wild-type mice

Interim phase I/II data show safety and systemic efficacy of RGX-121 in patients with MPS II

Sunshine Lake Pharma discovers teixobactin analogues

Preliminary phase II data for eganelisib plus nivolumab in advanced urothelial carcinoma

SIG-018 ameliorates symptoms of MPS II in preclinical models

New dihydroceramide desaturase inhibitors presented by Cincera Therapeutics

Dana-Farber Cancer Institute describes new CDK7/cyclin H inhibitors

New E-NPP 2 inhibitors identified at Boehringer Ingelheim

BeiGene patents MAP4K1 inhibitors

One-dose immunogenicity of BNT-162b2 vaccine among different groups of Israeli healthcare workers

Orchard Therapeutics reports data from trial of OTL-201 in MPS type III A

Multiorgan organoid gives developmental insights

First phase III data presented for nivolumab in patients with high-risk MIUC under radical surgery

FDA places partial clinical hold on atuzaginstat

Neuren reports phase I data on NNZ-2591 and plans to expand development into Prader-Willi syndrome

TLX-591-CDx for prostate cancer imaging receives first E.U. approval in Czech Republic

WHO lists two versions of AstraZeneca/Oxford COVID-19 vaccine for emergency use

Valbiotis gains French clearance to begin phase II study of TOTUM-070 to reduce LDL-cholesterol

InteRNA initiates first-in-human study of INT-1B3 in advanced solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...
Fortvita and Innovent patent new anti-TROP2/B7-H4 ADCs
BioWorld Science
Fortvita Biologics Inc. and Innovent Biologics (Suzhou) Co. Ltd. have jointly reported new antibody-drug conjugates (ADCs) comprising a bispecific antibody or...